Tumors augment monopoiesis and orchestrate the epigenetic reprogramming of CCR2+ classical monocytes (CMs) into tumor-associated macrophages that drive immune suppression to promote tumor progression, metastasis, and resistance to immunotherapy (1–3). This evidence concerns the gene CCR2 and neoplasm.